Praxis Precision Medicines, Inc. (PRAX)

Market Cap	1.42B
Revenue (ttm)	1.61M
Net Income (ttm)	-151.02M
Shares Out	18.64M
EPS (ttm)	-9.95
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,633
Open	76.12
Previous Close	77.00
Day's Range	74.00 - 76.47
52-Week Range	20.50 - 86.93
Beta	2.69
Analysts	Strong Buy
Price Target	146.33 (+92.03%)
Earnings Date	Nov 6, 2024

About PRAX

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 16, 2020
• Employees: 82
• Stock Exchange: NASDAQ
• Ticker Symbol: PRAX
• Website: https://praxismedicines.com

Analyst Forecast

According to 9 analysts, the average rating for PRAX stock is "Strong Buy." The 12-month stock price forecast is $146.33, which is an increase of 92.03% from the latest price.

Price Target

$146.33

(92.03% upside)

Analyst Consensus: Strong Buy